Protease resistant modified interferon-beta polypeptides

Details Protease resistant modified interferon-beta polypeptides Protease resistant modified interferon-beta polypeptides

2008-04-09

2011-11-15

Stoica, Elly-Gerald (Department: 1647)

Drug, bio-affecting and body treating compositions

Lymphokine

Interferon

C424S408000, C435S069510, C530S351000

Reexamination Certificate

active

08057787

ABSTRACT:
Protease resistant modified interferon-beta polypeptides, pharmaceutical compositions and methods of treatment administering the compositions are provided. The modified interferon-beta polypeptides are orally available; hence pharmaceutical compositions formulated for oral administration also are provided.

REFERENCES:
patent: 4044126 (1977-08-01), Cook et al.
patent: 4364923 (1982-12-01), Cook et al.
patent: 4414209 (1983-11-01), Cook et al.
patent: 4518584 (1985-05-01), Mark et al.
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4588585 (1986-05-01), Mark et al.
patent: 4753795 (1988-06-01), Bell et al.
patent: 4769233 (1988-09-01), Bell et al.
patent: 4793995 (1988-12-01), Bell et al.
patent: 4816396 (1989-03-01), Chang
patent: 4914033 (1990-04-01), Bell et al.
patent: 4937076 (1990-06-01), Lapidus
patent: 5096815 (1992-03-01), Ladner et al.
patent: 5183746 (1993-02-01), Shaked et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5510472 (1996-04-01), Reuel et al.
patent: 5545723 (1996-08-01), Goelz et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5723323 (1998-03-01), Kauffman et al.
patent: 5763239 (1998-06-01), Short et al.
patent: 5798208 (1998-08-01), Crea
patent: 5814485 (1998-09-01), Dorin et al.
patent: 5837500 (1998-11-01), Ladner et al.
patent: 5854049 (1998-12-01), Reed
patent: 5862514 (1999-01-01), Huse et al.
patent: 5871723 (1999-02-01), Strieter et al.
patent: 6001574 (1999-12-01), Short et al.
patent: 6013478 (2000-01-01), Wells et al.
patent: 6057103 (2000-05-01), Short
patent: 6096548 (2000-08-01), Stemmer
patent: 6117679 (2000-09-01), Stemmer
patent: 6127332 (2000-10-01), Goelz et al.
patent: 6132970 (2000-10-01), Stemmer
patent: 6153420 (2000-11-01), Sheppard
patent: 6156509 (2000-12-01), Schellenberger
patent: 6165793 (2000-12-01), Stemmer
patent: 6171820 (2001-01-01), Short
patent: 6174673 (2001-01-01), Short et al.
patent: 6180406 (2001-01-01), Stemmer
patent: 6238884 (2001-05-01), Short et al.
patent: 6323006 (2001-11-01), Ferreira et al.
patent: 6472512 (2002-10-01), LaFleur et al.
patent: 6514729 (2003-02-01), Bentzien
patent: 6531122 (2003-03-01), Pedersen et al.
patent: 6572853 (2003-06-01), Schneider-Fresenius
patent: 6608183 (2003-08-01), Cox
patent: 6800735 (2004-10-01), Whitty et al.
patent: 6906041 (2005-06-01), Braun
patent: 6962978 (2005-11-01), Pepinsky et al.
patent: 7144574 (2006-12-01), Rasmussen et al.
patent: 7611700 (2009-11-01), Gantier et al.
patent: 7647184 (2010-01-01), Vega et al.
patent: 7650243 (2010-01-01), Gantier et al.
patent: 2001/0043915 (2001-11-01), Frey
patent: 2002/0169290 (2002-11-01), Bornaes et al.
patent: 2003/0129203 (2003-07-01), Vega et al.
patent: 2003/0129584 (2003-07-01), Vega et al.
patent: 2003/0134351 (2003-07-01), Vega et al.
patent: 2003/0175694 (2003-09-01), Vega
patent: 2003/0224404 (2003-12-01), Vega et al.
patent: 2004/0132977 (2004-07-01), Gantier et al.
patent: 2004/0137581 (2004-07-01), Aguinaldo et al.
patent: 2005/0054052 (2005-03-01), Carr et al.
patent: 2005/0054053 (2005-03-01), Aguinaldo et al.
patent: 2005/0202438 (2005-09-01), Gantier et al.
patent: 2006/0020116 (2006-01-01), Gantier et al.
patent: 2006/0020396 (2006-01-01), Gantier et al.
patent: 2006/0094655 (2006-05-01), Guyon et al.
patent: 2006/0195268 (2006-08-01), Vega
patent: 2006/0247170 (2006-11-01), Guyon et al.
patent: 2006/0251619 (2006-11-01), Borrelly et al.
patent: 2007/0172459 (2007-07-01), Gantier et al.
patent: 2007/0224665 (2007-09-01), Gantier et al.
patent: 2007/0249532 (2007-10-01), Guyon et al.
patent: 2007/0254838 (2007-11-01), Gantier et al.
patent: 2007/0265187 (2007-11-01), Vukicevic et al.
patent: 2008/0003202 (2008-01-01), Vega
patent: 2008/0026993 (2008-01-01), Guyon et al.
patent: 2008/0038224 (2008-02-01), Guyon et al.
patent: 2008/0075672 (2008-03-01), Gantier et al.
patent: 2008/0102115 (2008-05-01), Oyhenart et al.
patent: 2008/0159977 (2008-07-01), Gantier et al.
patent: 2008/0194477 (2008-08-01), Gantier et al.
patent: 2008/0260820 (2008-10-01), Borrelly et al.
patent: 2008/0274081 (2008-11-01), Gantier et al.
patent: 2009/0123974 (2009-05-01), Gantier et al.
patent: 2009/0131318 (2009-05-01), Gantier et al.
patent: 2009/0238789 (2009-09-01), Guyon et al.
patent: 260350 (1992-02-01), None
patent: 1022335 (2000-07-01), None
patent: 95/23813 (1995-09-01), None
patent: 98/13487 (1998-04-01), None
patent: 98/48018 (1998-10-01), None
patent: 99/03887 (1999-01-01), None
patent: 00/68387 (2000-11-01), None
patent: 01/25438 (2001-04-01), None
patent: 01/32711 (2001-05-01), None
patent: 01/32844 (2001-05-01), None
patent: 01/44809 (2001-06-01), None
patent: 01/61344 (2001-08-01), None
patent: 01/86291 (2001-11-01), None
patent: 02/16606 (2002-02-01), None
patent: 02/074783 (2002-09-01), None
patent: 03/018820 (2003-03-01), None
patent: 03/023032 (2003-03-01), None
patent: 2004/022593 (2004-03-01), None
patent: 2004/022747 (2004-03-01), None
patent: 2004/031352 (2004-04-01), None
patent: 2004/087753 (2004-10-01), None
patent: 2005/003157 (2005-01-01), None
patent: 2006/020580 (2006-02-01), None
patent: 2006/024547 (2006-03-01), None
patent: 2006/048777 (2006-05-01), None
patent: 2006/120580 (2006-11-01), None
patent: 2007/110230 (2007-10-01), None
patent: 2008/065372 (2008-06-01), None
patent: 2009/152944 (2009-12-01), None
Bernkop-Schnürch, A. The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins J. Controlled release, 52, 1-16, 1998.
Keil B, Specificity of proteolysis—Springer Verlag, pp. 1, 2, 6, 102-104, 107-108, 201, ISBN0-387-53118-1, 1992.
Runkel et al., Systematic Mutational Mapping of Sites on Human Interferon beta That Are Important for Receptor Binding and Functional Activity, Biochemistry, 39, 2538-2551, 2000.
Bernkop-Schnurch “The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins,” J. Controlled Release, 52:1-16 (1998).
Descamps et al. “Gelatinase B is diabetogenic in acute and chronic pancreatitis by cleaving insulin,” FASEB J, 17:887-889 (2003).
Higashi et al., “Structure and expression of a cloned cDNA for mouse interferon-beta,” J Biol Chem 258(15):9522-9529 (1983).
Karpusas et al. “The crystal structure of human interferon at 2.2 angstrom resolution,” Proc. Natl. Acad. Sci. USA, 94:11813-11818 (1997).
Lee et al. “Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis: A longitudinal clinical and MRI study,” Brain, 122:191-197 (1999).
Matheux et al. “Macaque Lymphocytes Transduced by a Constitutively Expressed Interferon Beta Gene Display an Enhanced Resistance to SIVmac251 Infection,” Human Gene Therapy 10:429-440 (1999).
Runkel et al., “Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity,” Biochemistry 39(10):2538-2551 (2000).
Beck-Sickinger, G., et al., “Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations,” European Journal of Biochemistry, 223:947-958, (1994).
Biron, C.A., et al., “Natural killer cells in antiviral defenses: function and regulation by innate cytokines,” Annual Review of Immunology, 17:189-220, (1999).
Boger, J., et al., “Surface probability profiles. A heuristic approach to the selection of synthetic peptide antigens,” Reports of the Sixth International Congress in Immunology, p. 250, (1986).
Briand, L., et al., “Impact of the lysine-188 and aspartic acid-189 inversion on activity of trypsin,” FEBS Letters, 442(1):43-47, (1999).
Dayhoff, M.O., et al., “A model of evolutionary changes in proteins,” Atlas of Protein Sequence and Structure, 5(3):345-352, (1978).
Deng, W.P. and J.A. Nickloff, “Site-directed mutagenesis of virtually any plasmid by eliminating a unique site,” Analytical Biochemistry, 200:81-88, (1992).
Diaz, M.O., et al., “Nomenclature of the human

Affiliated with

Also associated with

Rating

Protease resistant modified interferon-beta polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Protease resistant modified interferon-beta polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protease resistant modified interferon-beta polypeptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4279644